TY - JOUR
T1 - The Alzheimer's Disease Neuroimaging Initiative
T2 - Progress report and future plans
AU - Weiner, Michael W.
AU - Aisen, Paul S.
AU - Jack, Clifford R.
AU - Jagust, William J.
AU - Trojanowski, John Q.
AU - Shaw, Leslie
AU - Saykin, Andrew J.
AU - Morris, John C.
AU - Cairns, Nigel
AU - Beckett, Laurel A.
AU - Toga, Arthur
AU - Green, Robert
AU - Walter, Sarah
AU - Soares, Holly
AU - Snyder, Peter
AU - Siemers, Eric
AU - Potter, William
AU - Cole, Patricia E.
AU - Schmidt, Mark
PY - 2010/5
Y1 - 2010/5
N2 - The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
AB - The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
KW - ADNI
KW - Alzheimer's disease
KW - Amyloid
KW - MRI
KW - Memory
KW - PET
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=77955474351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955474351&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2010.03.007
DO - 10.1016/j.jalz.2010.03.007
M3 - Article
C2 - 20451868
AN - SCOPUS:77955474351
SN - 1552-5260
VL - 6
SP - 202-211.e3
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 3
ER -